Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout

Trial Profile

Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors Savient Pharmaceuticals

Most Recent Events

  • 15 Nov 2023 Results of analysis assessing potential baseline factors that may influence urate-lowering response to pegloticas using data from Phase 3 pegloticase registration and MIRROR RCT2 trials presented at the ACR Convergence 2023
  • 06 Jan 2021 Results of post-hoc analysis of two studies (NCT00325195 & NCT01356498) assessing factors associated with gout flares in subjects treated with pegloticase, published in the Clinical and Experimental Rheumatology.
  • 21 Mar 2019 According to an AMPEL BioSolutions media release, results evaluating the characteristics and response to pegloticase of patients with chronic refractory gout with and without clinically apparent tophi, from two clinical trials, (NCT00325195, NCT01356498) were published in Rheumatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top